Cover Image
市場調查報告書

間質幹細胞 (MSC) :產品、技術的進步和各種用途

Mesenchymal Stem Cells - Advances & Applications (2018)

出版商 BIOINFORMANT WORLDWIDE, LLC 商品編碼 234291
出版日期 內容資訊 英文 216 Pages
訂單完成後即時交付
價格
Back to Top
間質幹細胞 (MSC) :產品、技術的進步和各種用途 Mesenchymal Stem Cells - Advances & Applications (2018)
出版日期: 2018年01月23日 內容資訊: 英文 216 Pages
簡介

本報告提供間質幹細胞 (MSC)的市場調查,幹細胞及間質幹細胞 (MSC)的概要,各種類型,臨床性用途的發展與變化,臨床研究、臨床開發趨勢,已上市產品概要,各種用途、支援疾病趨勢,企業間的聯盟等的配合,主要企業、產品的簡介等彙整資料。

第1章 報告概要

第2章 簡介

第3章 尖端醫療醫藥品 (ATMP:ADVANCED THERAPY MEDICINAL PRODUCTS)

  • 主要的對象領域
  • 已上市ATMP的價格
  • FDA核准完畢ATMP
  • EC已核准ATMP

第4章 幹細胞:概要

  • 胚胎幹細胞 (ESC)
  • 誘導性多功能幹細胞 (iPSC)
  • 幹細胞來源的特殊化細胞的各種類型
  • 人體的幹細胞的各種類型
    • 人類胚胎幹細胞 (hESC)
    • EG細胞
    • 胎生幹細胞
    • 臍帶幹細胞
  • 成體幹細胞
    • 造血幹細胞 (HSC)
    • 間質幹細胞 (MSC)
    • 神經幹細胞 (NSC)
  • 各種幹細胞的特徵
  • 醫療的用途

第5章 間質幹細胞 (MSC):概要

  • MSC的新的名稱
  • MSC的功能
  • MSC的資源
  • hMSC的分離、培養
  • MSC的各種類型的特徵
  • hMSC可治療的慢性疾病
  • 成為MSC細胞治療的對象的一般疾病
  • 細胞治療中MSC的優點
  • MSC和其他幹細胞類型的比較
  • 自體MSC的缺點和同類MSC的優點
  • MSC的作用機制
  • 組織再生
  • 免疫修飾
  • MSC的製造

第6章 MSC的臨床性用途

  • GvHD
  • 心臟血管修復
  • 肝疾病
  • 骨/軟骨疾病的MSC
  • 已核准MSC產品
    • Cartistem
    • Stempeucel
    • MPC (Mesenchymal Precursor Cell):Mesoblast
    • Cupistem
    • Prochymal
    • AlloStem
    • Cellgram-AMI
    • Osteocel Plus
    • Trinity Evolution
    • CardioRel
    • Temcell
  • 含MSC的骨基材
    • 成本
    • 組織工程的整形外科產品候補
  • 已核准細胞治療產品的價格

第7章 幹細胞研究的出版、資金、專利

  • MSC相關科學論文
  • 全球幹細胞研究
  • NIH的MSC研究資金
  • 專利環境

第8章 MSC相關的臨床試驗:概要

  • 目前臨床試驗方案
  • MSC相關的臨床試驗的地區的佔有率
  • 臨床試驗的資源
  • 現在實驗中的支援疾病
  • 現行的臨床試驗
  • 臨床試驗的到目前為止的成果
  • 大學主導的主要的臨床實驗
  • 企業主導的主要的臨床實驗
  • 心血管疾病
  • 骨關節炎
  • 創傷治療
  • 肝疾病
  • 肺部疾病
  • 眼障礙
  • 腎障礙
  • 糖尿病
  • 移植物抗宿主病 (GvHD)
  • 發炎性腸道疾病
  • 多發性硬化症
  • 特定疾病的MSC臨床研究狀況
    • 移植物抗宿主病 (GvHD)
    • OA & RA
    • 發炎性呼吸道、肺部疾病
    • 多發性硬化症 (MS)
    • 發炎性腸道疾病 (IBD)
    • 基因改造MSC

第9章 聯盟的配合措施

第10章 市場分析

第11章 企業簡介

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

Mesenchymal stem cells (MSCs) are multipotent cells that can differentiate into a variety of cell types, including osteoblasts, chondrocytes, myocytes, adipocytes, and potentially other cell types.

In addition to secreting factors that can stimulate tissue repair, MSCs can substantially alter their microenvironment, exerting effects that are both anti-inflammatory and anti-fibrotic. MSCs are advantageous over other stem cells types for a variety of reasons, including that they are immuno-privileged, making them an advantageous cell type for allogenic transplantation. MSCs appear to be an exceptionally promising tool for cell therapy, because of their unusual advantages, which include availability, expandability, transplantability, and ethical implications.

Interest in therapeutic applications of human MSCs arises from their diverse ability to differentiate into a range of cell types, as well as their ability to migrate to sites of tissue injury/inflammation or tumor growth. Additionally, MSCs well-suited for use in the exponential growth area of 3D printing, because of their capacity to form structural tissues.

Growing attention is now being given to manufacturing technologies to support commercial-scale production of MSCs. Numerous market competitors are also exploring commercialization strategies for MSC-derived exosomes, because exosomes represent a novel strategy for accessing the therapeutic effects of stem cells without the risks and difficulties of administering the cells to patients.

As the most common stem cell type being used in regenerative medicine, there is substantial potential for growth within the MSC market. Today, there are more than 40,000 scientific publications published about the cell type[1], more than 800 clinical trials underway worldwide[2], and Google Trend data reveals that MSC searches are more than twice as common as the next most common adult stem cell type[3].

Burgeoning Market for Mesenchymal Stem Cells (MSCs)

Mesenchymal stem cells (MSCs) are the most utilized cell type within the regenerative medicine industry. To support this rapidly expanding marketplace, this 200+ page global strategic report presents trend rate data for MSC market, including rates of MSC patents, grants, scientific publications, and clinical trials, as well as social analytics that identify online behavior related to MSCs.

The report describes the current status of mesenchymal stem cell (MSC) research, ongoing clinical trials involving MSCs, late stage MSC clinical trials, and uses of MSCs in cell therapy. It explores recent advances in MSC products and technologies, identifies research priorities by market segment, and assesses 73 leading competitors within the MSC marketplace.

Because MSC therapy is an integrated component of Advanced Therapy Medicinal Products (ATMPs), this market report also provides an introduction to ATMPs.

For pharmaceutical companies, the report reveals how advances in MSC research can reveal potential new drug targets, improve methods of drug delivery, and provide personalized treatment strategies. With “Big Pharma” diversifying their product development pipelines by investing in cell therapy companies, MSC companies now represent promising candidates for collaboration, investment, and acquisition.

Based in Washington, DC, BioInformant is first and only market research firm to specialize in the stem cell industry. Unlike other publishers that hire analysts from foreign countries, BioInformant is an American-based company with more than a decade of experience with tracking the stem cell market (2006 to present). BioInformant compiled this global strategic report using interviews with more than 90 individuals from across the stem cell industry.

BioInformant conducted interviews with representatives from Cynata Therapeutics (first company to bring a iPSC-derived MSC therapeutic product into a clinical trial), RoosterBio (global leader in MSC manufacturing technology that can produce to tens of billions of cells in suspension bioreactors), Pluristem Therapeutics (commercializing placenta-derived mesenchymal-like adherent stromal cells in late-stage clinical trials), BioEden (leading company preserving MSCs derived from dental tissues), Regenexx (world's leading provider of MSC therapies for orthopedic applications), and many more.

The report also incorporates secondary findings from SEC filings, company websites, press releases, investor presentations, government policy documents, Google Trends, and Google Adwords.

Footnotes:

[1] PubMed.gov Search; Date: 01/14/2017. Search terms: “mesenchymal stem cell” OR “mesenchymal stem cells” OR “mesenchymal stromal cell” OR “mesenchymal stromal cells”.

[2] ClinicalTrials.gov Search; Date: 01/14/2017. Search terms: “mesenchymal stem cell” OR “mesenchymal stem cells” OR “mesenchymal stromal cell” OR “mesenchymal stromal cells”.

[3]Google Trends Search; Date: 01/14/2017. Search Terms Compared: “mesenchymal stem cells” vs. “hematopoietic stem cells” vs. “neural stem cells”.

Table of Contents

1. REPORT OVERVIEW

  • 1.1. Statement of the Report
  • 1.2. Executive Summary

2. INTRODUCTION

3. ADVANCED THERAPY MEDICINAL PRODUCTS (ATMPs)

  • 3.1. Major Therapeutic Areas of Interests in ATMPs Sector
  • 3.2. Price of Market-Stage ATMPs
  • 3.3. FDA-Approved ATMPs
  • 3.4. EC-Approved ATMPs

4. STEM CELLS: A BRIEF OVERVIEW

  • 4.1. Embryonic Stem Cells (ESCs)
  • 4.2. Induced Pluripotent Stem Cells (iPSCs)
  • 4.3. Types of Specialized Cells Derived from Stem Cells
  • 4.4. Types of Stem Cells in Human Body
    • 4.4.1. Human Embryonic Stem Cells (hESCs)
    • 4.4.2. Embryonic Germ Cells (EG-Cells)
    • 4.4.3. Fetal Stem Cells
    • 4.4.4. Umbilical Cord Stem Cells
  • 4.5. Adult Stem Cells
    • 4.5.1. Hematopoietic Stem Cells (HSCs)
    • 4.5.2. Mesenchymal Stem Cells (MSCs)
    • 4.5.3. Neural Stem Cells (NSCs)
  • 4.6. Characteristics of Different Types of Stem Cells
  • 4.7. Applications of Stem Cells in Medicine

5. MESENCHYMAL STEM CELLS (MSCs): A DETAILED OVERVIEW

  • 5.1. A New Name for MSCs
    • 5.1.1. History and Timeline of MSCs Nomenclature
  • 5.2. Functions of MSCs
  • 5.3. Sources of MSCs
  • 5.4. Isolation and Culturing of hMSCs
    • 5.4.1. Cell Surface Markers in MSCs
    • 5.4.2. In Vitro Differentiation Potential of MSCs
  • 5.5. Key Features of Different Types of MSCs
  • 5.6. Chronic Diseases Treatable by hMSCs
  • 5.7. Common Diseases Registered for MSC-Based Cell Therapy
  • 5.8. Advantages of MSCs in Cell Therapy
  • 5.9. Comparison of MSCs with Other Stem Cell Types
  • 5.10. Drawbacks of Autologous MSCs and Advantages of Allogeneic MSCs
    • 5.10.1. Application Strategies for Allogeneic MSCs
  • 5.11. Mechanism of Action of MSCs in Treating Diseases
  • 5.12. Tissue Regeneration
  • 5.13. Immune Modulation
  • 5.14. Manufacture of MSCs
    • 5.14.1. Safety and Potency Assays
    • 5.14.2. Surface Markers of MSC
    • 5.14.3. BM-MNC Isolation and Plating
    • 5.14.4. Passaging and Harvesting
    • 5.14.5. Cryopreservation of MSCs
    • 5.14.6. Donor Eligibility and Cell Collection
    • 5.14.7. Regulatory Framework of MSC Therapies
    • 5.14.8. Contract Development and Manufacturing Organizations (CDMO)

6.1. MSCs for GvHD

  • 6.2. MSCs for Cardiovascular Repair
  • 6.3. MSCs for Liver Disease
  • 6.4. MSC for Bone/Cartilage Disease
  • 6.5. Approved MSC-Based Products
    • 6.5.1. Cartistem
    • 6.5.2. Stempeucel
    • 6.5.3. Mesenchymal Precursor Cells (MPCs) from Mesoblast
    • 6.5.4. Cupistem
    • 6.5.5. Prochymal
    • 6.5.6. AlloStem
    • 6.5.7. Cellgram-AMI
    • 6.5.8. Osteocel Plus
    • 6.5.9. Trinity Evolution
    • 6.5.10. CardioRel
    • 6.5.11. Temcell
  • 6.6. Bone Matrices Containing MSCs
    • 6.6.1. Cost of Bone Matrices Containing MSCs
    • 6.6.2. Tissue Engineered Orthopedic Product Candidates Containing MSCs
  • 6.7. Pricing of Approved Cell Therapy Products

7. STEM CELL RESEARCH PUBLICATIONS, FUNDING AND PATENTS

  • 7.1. Volume of Scientific Papers Published on MSCs
    • 7.1.1. Number of Publications on MSCs by Major Applications
  • 7.2. Stem Cell Research around the World
  • 7.3. NIH Funding for MSCs Research
  • 7.4. Stem Cell Patents Landscape

8. CLINICAL TRIALS INVOLVING MSCS: AN OVERVIEW

  • 8.1. Current Clinical Trial Scenario
  • 8.2. Geographical Share of MSC Clinical Trials
    • 8.2.1. Number of Clinical Trials using MSCs by Geography/Country
  • 8.3. Sources of MSCs for Current Clinical Trials
  • 8.4. Diseases Addressed by MSCs in the Ongoing Clinical Trials
  • 8.5. Active Clinical Trials using MSCs
  • 8.6. MSC Clinical Trial Outcomes, 2011-2016
  • 8.7. Selected Clinical Trials Sponsored by Universities
    • 8.7.1. Celal Bayar University (NCT02824393)
    • 8.7.2. University of Jordan (NCT02118519)
    • 8.7.3. Ankara University (NCT03106662)
    • 8.7.4. University Hospital of Liege (NCT00504803)
    • 8.7.5. Acibadem University (NCT02285673)
    • 8.7.6. University of Sao Paulo (NCT01297972)
    • 8.7.7. Cairo University (NCT02387749)
  • 8.8. Selected Clinical Trials Sponsored by Cell Therapy Companies
    • 8.8.1. Scinow Biotechnology Co., Ltd. (NCT03184935)
    • 8.8.2. Mesoblast Ltd. (NCT00294112)
    • 8.8.3. Cellular Biomedicine Group Ltd. (NCT01809769)
    • 8.8.4. Alliancells Bioscience Corporation Ltd. (NCT01573923)
    • 8.8.5. Pharmicell Co., Ltd. (NCT01676441)
    • 8.8.6. Shenzhen Hometcorn Biotechnology Co., Ltd.
    • 8.8.7. Sclnow Biotechnology Co., Ltd. (NCT03180450)
  • 8.9. Clinical Trials using MSCs for Cardiovascular Diseases
    • 8.9.1. Corporate Investment in Cardiovascular Diseases using MSC Therapy
      • 8.9.1.1. MPC-150-IM from Mesoblast
      • 8.9.1.2. CLBS10 from Caladrius
      • 8.9.1.3. C-Cure from Celyad
      • 8.9.1.4. Ixmyelocel-T from Vericel
      • 8.9.1.5. MultiStem from Athersys
  • 8.10. MSCs for Osteoarthritis
  • 8.11. MSCs in Wound Healing
  • 8.12 MSCs for Liver Diseases
  • 8.13. MSCs for Lung Disorders
  • 8.14. Clinical Trials using MSCs for Eye Disorders
  • 8.15 MSCs for Kidney Disorders
  • 8.16. MSCs for Diabetes
  • 8.17. MSCs for Graft vs. Host Disease (GvHD)
  • 8.18. MSCs for Inflammatory Bowel Diseases
  • 8.19. MSCs for Multiple Sclerosis
  • 8.20. Status of MSC Clinical Research in Specific Diseases
    • 8.20.1. Graft v. Host Disease (GvHD)
    • 8.20.2. OA & RA
    • 8.20.3. Inflammatory Airway and Pulmonary Diseases
    • 8.20.4. Multiple Sclerosis (MS)
    • 8.20.5. Inflammatory Bowel Disease (IBD)
    • 8.20.6. Genetically Engineered MSCs

9. PARTNERING ACTIVITIES IN CELL THERAPY SECTOR

  • 9.1. Collaboration between Lonza and Nikon
  • 9.2. Hitachi's Purchase of PCT from Caladrius Biosciences
  • 9.3. Collaboration between Regeneus Ltd. and Asahi Glass. Co. on Progenza
  • 9.4. Collaboration between RepliCel Life Sciences and Shiseido Co., Ltd.
  • 9.5. Collaboration between SanBio Life Sciences and Sumitomo
  • 9.6. Partnership and License Agreement between Healios K.K. and Athersys Inc.
  • 9.7. Cell Therapy Ltd.'s License to Daiichi Sankyo
  • 9.8. TiGenix's License to Takeda Pharmaceuticals
  • 9.9. Celyad's License to Ono Pharmaceuticals
  • 9.10. Collaboration Kolon Life Sciences and Mitsubishi Tanabe
  • 9.11. Collaboration between Steminent Biotherapeutics and ReproCELL Inc.
  • 9.12. Kite Pharma's Partnership with Daiichi Sankyo
  • 9.13. Acquisition of Cellular Dynamics by Fujifilm Holdings
  • 9.14. License Agreement between Cynata Therapeutics and Fujifilm
  • 9.15. Gilead to Acquire Kite Pharma
  • 9.16. Big Pharma's Strategy in Advanced Therapy Sector
    • 9.16.1. Collaboration between Sangamo and Pfizer
    • 9.16.2. Acquisition of 3D Printing Systems from Tissue Regeneration Systems by DePuy Synthes Products (J&J)
    • 9.16.3. New JLABS Opened by J&J
    • 9.16.4. Collaboration between GSK and Miltenyl Biotec
  • 9.17. Big Pharma's Interest in Cell Therapy
    • 9.17.1. GlaxoSmithKline (GSK)
    • 9.17.2. Pfizer
    • 9.17.3. Novartis
    • 9.17.4. AstraZeneca
    • 9.17.5. Roche
    • 9.17.6. Johnson & Johnson
    • 9.17.7. Sanofi
  • 9.18. Big Pharma Strategy in Advanced Therapies
    • 9.18.1. Value of Big Pharma Deals in Cell and Gene Therapy
  • 9.19. Recent Events in Advanced Therapies Sector
  • 9.20. Geographical Distribution of Cell Therapy Companies

10. MARKET ANALYSIS

11. COMPANY PROFILES

  • 11.1. AdiCyte
  • 11.2. AdiSave
  • 11.3. AlloSource Inc.
    • 11.3.1. AlloStem
  • 11.4. American CryoStem Corporation
    • 11.4.1. Clinical Adipose-Tissue Platform
  • 11.5. Anterogen Co., Ltd.
    • 11.5.1. Cupistem Injection
  • 11.6. Apceth Biopharma GmbH
    • 11.6.1. Apceth's Allogeneic MSC Platform
      • 11.6.2. Apceth's Genetically-Engineered MSCs
  • 11.7. Athersys Inc.
    • 11.7.1. MultiStem
  • 11.8. Astarte Biologics Inc.
  • 11.9. BioCardia Inc.
    • 11.9.1. Product Pipeline
  • 11.10. BioRestorative Therapies Inc.
    • 11.10.1. brtxDISC
    • 11.10.2. ThermoStem Program
  • 11.11. Bone Therapeutics SA
    • 11.11.1. Collaborators
  • 11.12. Brainstorm Cell Therapeutics
    • 11.12.1. NurOwn Technology
  • 11.13. Caladrius Biosciences Inc.
    • 11.13.1. CLBS03
    • 11.13.2. CLBS12
  • 11.14. Capricor Therapeutics Inc.
    • 11.14.1. CAP-1002
    • 11.14.2. CAP-2003
  • 11.15. Cell Applications Inc.
  • 11.16. Cell Cure Neurosciences Ltd.
    • 11.16.1. OpRegen
  • 11.17. CellGenix Technologie Transfer GmbH
    • 11.17.1. Cell Types Offered
    • 11.17.2. CellGro Cytokines
    • 11.17.3. Serum-Free Media
    • 11.17.4. Supplements and Cells
  • 11.18. CellProthera SAS
    • 11.18.1. ProtheraCytes
  • 11.19. Celltex Therapeutics Corporation
  • 11.20. Cellular Dynamics International Inc.
  • 11.21. Celprogen Inc.
  • 11.22. Cell Therapies Pty Ltd.
    • 11.22.1. Contract Manufacturing Services
    • 11.22.2. Apheresis Management Services
    • 11.22.3. Clinical Trial Support Services
    • 11.22.4. Consultancy & Advisory Services
  • 11.23. Celvive Inc.
    • 11.23.1. The StemCell Bag
  • 11.24. Cesca Therapeurics Inc.
    • 11.24.1. CAR-TXpress
    • 11.24.2. AutoXpress (AXP)
    • 11.24.3. Point-of-Care Solutions for Cell-Based Therapies (PXP)
    • 11.24.4. CellXpress
  • 11.25. Celyad SA
  • 11.26. Cyagen Biosciences Inc.
    • 11.26.1. Cells
    • 11.26.2. Media
  • 11.27. Cynata Therapeucics Ltd.
    • 11.27.1. Cymerus Platform Technology
  • 11.28. Cytori Therapeutics Inc.
    • 11.28.1. Cytori Cell Therapy
  • 11.29. Escape Therapeutics Inc.
  • 11.30. Future Health BioBank
  • 11.31. Gamida Cell Ltd.
    • 11.31.1. NAM Technology
    • 11.31.2. NiCord
    • 11.31.3. Cordin
    • 11.31.4. NAM-NK Cells
  • 11.32. Intercytex Ltd.
    • 11.32.1. ICH-RHY
  • 11.33. International Stem Cell Corp.
  • 11.34. Invitrx Therapeutics Inc.
    • 11.34.1. Therapeutic Procedures
    • 11.34.2. Invitra ECM Suspension
    • 11.34.3. Cosmetic Procedures
  • 11.35. JCR Pharmaceuticals Co., Ltd.
    • 11.35.1. Temcell HS Inj.
  • 11.36. Kadimastem Ltd.
    • 11.36.1. Solution for Diabetes
    • 11.36.2. Solution for Neurodegenerative Diseases
  • 11.37. Kiadis Pharma N.V.
    • 11.37.1. ATIR101
    • 11.37.2. ATIR201
  • 11.38. Kite Pharma Inc.
    • 11.38.1. Kite Pharma's Research
  • 11.39. Life Sciences Inc.
    • 11.39.1. Technology
    • 11.39.2. RCT-01
    • 11.39.3. RCS-01
    • 11.39.4. RCH-01
    • 11.39.5. RCI-02
  • 11.40. Living Cell Technologies Ltd.
    • 11.40.1. NTCELL
  • 11.41. Lonza Group Ltd.
  • 11.42. Magenta Therapeutics Inc.
    • 11.42.1. Magenta's Stem Cell Platform
  • 11.43. Medeor Therapeutics Inc.
    • 11.43.1. MDE-10X
  • 11.44. Medipost Co., Ltd.
    • 11.44.1. Cartistem
    • 11.44.2. Pneumostem
    • 11.44.3. Neurostem
  • 11.45. Mesoblast Inc.
    • 11.45.1. MPC-150-IM
    • 11.45.2. MPC-300-IV
    • 11.45.3. MPC-06-ID
    • 11.45.4. MSC-100-IV
    • 11.45.5. Temcell HS Injection
  • 11.46. NuVasive Inc.
    • 11.46.1. Osteocel
  • 11.47. Neuralstem Inc.
    • 11.47.1. NSI-189
  • 11.48. Octane Biotech Inc.
    • 11.48.1. Turn-Key Production System for Cell and Tissue Therapy
    • 11.48.2. Automated Bioreactors
    • 11.48.3. Atomically Enhanced Implants
    • 11.48.4. Drug-Enhanced Implants
    • 11.48.5. Cell-Enhanced Implants
  • 11.49. Organogenesis Inc.
    • 11.49.1. Apligraf
    • 11.49.2. Dermagraft
  • 11.50. Orthofix International N.V.
    • 11.50.1. BioStim
    • 11.50.2. Biologics
      • 11.50.2.1. Trinity ELITE
      • 11.50.2.2. Trinity Evolution
      • 11.50.2.3. VersaShield
      • 11.50.2.4. Collage
      • 11.50.2.5. AlloQuent
  • 11.51. Osiris Therapeutics Inc.
    • 11.51.1. Grafix
    • 11.51.2. BIO4
    • 11.51.3. Stravix
    • 11.51.4. Cartiform
  • 11.52. OxStem Ltd.
  • 11.53. PharmaCell B.V.
  • 11.54. Pharmicell Co. Ltd.
    • 11.54.1. Cellgram-AMI
  • 11.55. Pluristem Therapeutics Inc.
    • 11.55.1. PLX Products
    • 11.55.2. PLX-PAD
    • 11.55.3. PLX-R18
    • 11.55.4. Prochymal
  • 11.56. Precious Cells International Ltd.
  • 11.57. Promethera Biosciences S.A.
    • 11.57.1. HepaStem for ACLF
    • 11.57.2. HepaStem for NASH
    • 11.57.3. H2Stem
    • 11.57.4. Heparesc
  • 11.58. Provia Laboratories, LLC
  • 11.59. Regen BioPharma Inc.
    • 11.59.1. HemaXellerate (Phase I/II)
  • 11.60. Regeneus Ltd.
    • 11.60.1. Progenza
    • 11.60.2. RGSH4K
    • 11.60.3. Secretions
  • 11.61. Reliance Life Sciences Pvt. Ltd.
    • 11.61.1. CardioRel
  • 11.62. Reneuron Group plc
    • 11.62.1. CTX Cell Line
    • 11.62.2. hRPC
    • 11.62.3. Exosome Platform
  • 11.63. Stemedica Cell Technologies Inc.
    • 11.63.1. BioSmart Technology
    • 11.63.2. Clinical Pipeline
  • 11.64. StemGen Therapeutics
    • 11.64.1. Lipokraft
    • 11.64.2. Lipokraft Advance
    • 11.64.3. Amniokraft
  • 11.65. Stempeutics Research Pvt. Ltd.
    • 11.65.1. Stempeucel
    • 11.65.2. Stempeucare
    • 11.65.3. Stempeutron
  • 11.66. Stratatech Corp.
    • 11.66.1. StrataGraft
    • 11.66.2. ExpressGraft
  • 11.67. ThermoFischer Scientific Inc.
  • 11.68. TiGenix N.V.
    • 11.68.1. TiGenix's Pipeline
  • 11.69. U.S. Stem Cell Inc.
    • 11.69.1. MyoCell
    • 11.69.2. MyoCell SDF-1
    • 11.69.3. AdipoCell
  • 11.70. Vericel Corporation
    • 11.70.1. Ixmyelocel-T
    • 11.70.2. MACI
    • 11.70.3. Epicel
    • 11.70.4. Carticel
  • 11.71. ViaCyte Inc.
    • 11.71.1. VC-01
    • 11.71.2. VC-02
  • 11.72. Xintea AB
    • 11.72.1. XINMARK
    • 11.73. Zen-Bio Inc.

INDEX OF FIGURES

  • FIGURE 3.1: Major Indications of Advanced Therapy Clinical Trials
  • FIGURE 4.1: Differentiation of Stem Cells into Adult Specialized Cells
  • FIGURE 4.2: Differentiation of Embryonic Stem Cells into Adult Specialized Cells
  • FIGURE 4.3: Differentiation of Induced Pluripotent Stem Cells into Adult Specialized Cells
  • FIGURE 4.4: Types of Specialized Cells Derived from Stem Cells
  • FIGURE 4.5: Applications of Stem Cells
  • FIGURE 5.1: Types of Common Diseases Registered for MSC-Based Cell Therapy
  • FIGURE 5.2: Some Mechanisms of MSCs in Therapeutic Application
  • FIGURE 5.3: Steps in the Manufacturing Process of MSCs
  • FIGURE 6.1: Clinical Trials of MSCs Classified by Disease Type
  • FIGURE 7.1: Stem Cell Research Publications Landscape
  • FIGURE 7.2: Number of Published Scientific Papers on MSCs
  • FIGURE 7.3: Number of Publications on MSCs by Major Applications, 2016
  • FIGURE 8.1: Currently Active Clinical Trials using MSCs
  • FIGURE 8.2: MSC-Based Clinical Trials by Geography
  • FIGURE 8.3: Sources of MSCs used in Current Clinical Trials
  • FIGURE 8.4: Diseases Addressed by MSCs in the Ongoing Clinical Trials
  • FIGURE 9.1: Value of Deals Undertaken by Big Pharma in Gene and Cell Therapy Sector, 2016
  • FIGURE 9.2: Geographical Distribution of Cell Therapy Companies
  • FIGURE 10.1: Global Market for Mesenchymal Stem Cells and Products, 2016-2022
Back to Top